Management of allergic rhinitis with leukotriene receptor antagonists versus selective H1-antihistamines: a meta-analysis of current evidence
Open Access
- 29 June 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Allergy, Asthma & Clinical Immunology
- Vol. 17 (1), 1-12
- https://doi.org/10.1186/s13223-021-00564-z
Abstract
Background Inconsistencies remain regarding the effectiveness and safety of leukotriene receptor antagonists (LTRAs) and selective H1-antihistamines (SAHs) for allergic rhinitis (AR). A meta-analysis of randomized controlled trials (RCTs) was conducted to compare the medications. Methods Relevant head-to-head comparative RCTs were retrieved by searching the PubMed, Embase, and Cochrane’s Library databases from inception to April 20, 2020. A random-effects model was applied to pool the results. Subgroup analyses were performed for seasonal and perennial AR. Results Fourteen RCTs comprising 4458 patients were included. LTRAs were inferior to SAHs in terms of the daytime nasal symptoms score (mean difference [MD]: 0.05, 95% confidence interval [CI] 0.02 to 0.08, p = 0.003, I 2 = 89%) and daytime eye symptoms score (MD: 0.05, 95% CI 0.01 to 0.08, p = 0.009, I 2 = 89%), but were superior in terms of the nighttime symptoms score (MD: − 0.04, 95% CI − 0.06 to − 0.02, p < 0.001, I 2 = 85%). The effects of the two treatments on the composite symptom score (MD: 0.02, 95% CI − 0.02 to 0.05, p = 0.30, I 2 = 91%) and rhinoconjunctivitis quality-of-life questionnaire (RQLQ) (MD: 0.01, 95% CI − 0.05 to 0.07, p = 0.71, I 2 = 99%) were similar. Incidences of adverse events were comparable (odds ratio [OR]: 0.97, 95% CI 0.75 to 1.25, p = 0.98, I 2 = 0%). These results were mainly obtained from studies on seasonal AR. No significant publication bias was detected. Conclusions Although both treatments are safe and effective in improving the quality of life (QoL) in AR patients, LTRAs are more effective in improving nighttime symptoms but less effective in improving daytime nasal symptoms compared to SAHs.Keywords
This publication has 40 references indexed in Scilit:
- Clinical Studies of Combination Montelukast and Loratadine in Patients with Seasonal Allergic RhinitisJournal of Asthma, 2009
- Sleep disturbance in persistent allergic rhinitis measured using actigraphyAnnals of Allergy, Asthma & Immunology, 2009
- Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patientsAnnals of Allergy, Asthma & Immunology, 2008
- Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2006
- Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitisBritish Journal of Clinical Pharmacology, 2004
- Montelukast improves symptoms of seasonal allergic rhinitis over a 4‐week treatment periodAllergy, 2003
- Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2003
- Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fallAnnals of Allergy, Asthma & Immunology, 2002
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trialJournal of Allergy and Clinical Immunology, 2000